Amzak Health Investors

What Amzak Health Investors does

Amzak Health Investors is a New York-based evergreen venture capital firm founded in 2015 by Joyce Erony that invests in private and select public life science companies developing first-in-class and best-in-class technologies in medtech and biotech. The firm invests across the healthcare spectrum, including therapeutics, medical devices, diagnostics, and services, with a stated focus on companies addressing unmet medical needs from pre-clinical through commercialization stages. Its portfolio spans therapeutic areas including neuromodulation (Shiratronics, Nervonik), histotripsy (HistoSonics), women's health (Gynesonics), spine (Synergy Spine Solutions), embolic protection (Contego Medical), cardiovascular devices (Neuros Medical), orthopedics (Miach Orthopaedics), ENT (ENT Specialty Partners), and oncology (Thryv Therapeutics).

The firm operates with a small team of experienced biotech and medtech investors led by Managing Partner Joyce Erony (former Managing Director at Signet Healthcare Partners) and Partner Tony Natale (former Managing Partner at Aperture Venture Partners, joined 2023), supported by Principal Dave Siet and Operations Manager Margarita Bernard. The team maintains active board positions across portfolio companies and provides strategic partnership alongside capital. As an evergreen fund, Amzak Health is not constrained by traditional fund lifecycle limits, enabling long-term support across portfolio company development stages.

Revenue mechanics for Amzak Health derive from successful portfolio company exits, including IPOs and strategic acquisitions. The firm reports a track record of more than 12 exits to strategic investors, three IPOs, and portfolio companies that have generated more than $20 billion in cumulative exit value. Notable realizations include HistoSonics' $2.25 billion acquisition in 2025 and Gynesonics' acquisition by Hologic in 2025. The firm does not publicly disclose fund size, AUM, or revenue figures, and capital deployment occurs through direct investment relationships, typically leading or co-leading financing rounds with syndicate partners including USVP, Lumira Ventures, Shangbay Capital, Foothill Ventures, and Elevage Medical Technologies.

Name

Amzak Health Investors

Legal name

Amzak Health

Website

https://amzakhealth.com/

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

Amzak Health Investors is a New York-based evergreen venture capital firm founded in 2015 that invests in first-in-class and best-in-class medtech and biotech companies across the healthcare sector, from pre-clinical stages through commercialization.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

NAICS

Portfolio Management and Investment Advice (523940), Funds, Trusts, and Other Financial Vehicles (525)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Healthcare venture capital
• Life science investing
• Medtech investment
• Biotech investment
• Evergreen fund

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations

Revenue model

1. Investment returns from portfolio companies: As a venture capital firm, Amzak Health generates returns through successful exits of portfolio companies, including IPOs and acquisitions. They have a track record of success with more than 12 exits to strategic investors and three IPOs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Amzak Health Investors operates as an evergreen venture fund that invests in private and select public life science companies across the healthcare sector. The firm provides capital and strategic partnership to medtech and biotech companies developing first-in-class and best-in-class treatments, investing across the spectrum from early-stage through commercialization. The firm supports portfolio companies throughout their lifecycle, working with management teams to achieve value inflection points.

Product overview

Amzak Health is a venture capital and investment management firm that does not offer a product or service in the traditional SaaS/software sense. As an evergreen fund, the firm provides capital investment and strategic partnership to private and select public companies in the medtech and biotech sectors. The firm's portfolio includes investments across multiple therapeutic areas and medical device categories, including neuromodulation, histotripsy, spine solutions, women's health, embolic protection, and cardiovascular devices. The portfolio companies operate independently and Amzak Health's role is as an investor and board-level partner rather than a product provider.

Differentiator

Problem solved

Functional benefit

Products and services

• Evergreen Healthcare Venture Fund

Quantifiable outcome

• 25 investments made by Managing Partner resulting in 12+ exits to strategic investors and 3 IPOs
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Frazier Healthcare Partners: Healthcare-dedicated firm investing across life sciences, medtech, and healthcare services at venture and growth stages. Closely comparable to Amzak in sector focus, stage range, and partnership-driven model with portfolio company operators.
• OrbiMed: One of the largest dedicated healthcare investment firms globally, investing across biopharmaceuticals, medical devices, and diagnostics from venture through public markets. Highly comparable to Amzak given its focus on first-in-class and best-in-class life science companies across similar stages.
• RA Capital Management: Healthcare-focused investment firm investing across public and private companies in therapeutics, medtech, and diagnostics. Comparable to Amzak in its willingness to invest across private and select public life sciences companies with thematic healthcare focus.
• Versant Ventures: Healthcare-focused venture capital firm investing across biopharma, medical devices, and healthcare services. Comparable to Amzak in stage range, therapeutic breadth, and emphasis on breakthrough science with experienced operating partners.
• HealthQuest Capital: Healthcare-focused growth and venture capital firm investing across medtech, diagnostics, and healthcare services. Comparable to Amzak in stage flexibility and concentration on commercial-stage healthcare innovation.
• Atlas Venture: Early-stage life sciences venture capital firm focused on building biotech startups across therapeutics and modalities. Comparable to Amzak in life sciences focus, science-driven underwriting, and early-stage entry approach.
• Longitude Capital: Healthcare-focused venture and growth capital firm investing across therapeutic, medical device, and healthcare services companies. Comparable to Amzak in stage range, sector focus, and emphasis on commercial inflection points.
• 5AM Ventures: Early-stage life sciences venture capital firm focused on building biotech companies from platform technologies. Similar to Amzak in stage focus (pre-clinical through clinical) and science-driven investment approach in therapeutics and platforms.

Broad incumbents

• ARCH Venture Partners: Large early-stage venture firm focused on founding and building life sciences and physical sciences companies. Comparable to Amzak in science-first orientation and stage range, though substantially larger in fund size and portfolio breadth.
• Novo Holdings: Major global healthcare investor through Novo Ventures and other arms, investing across life sciences at scale. Broader and far larger than Amzak, but operates in the same healthcare venture space with similar science-driven approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments23 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amzak Health Investors